

## CURRICULUM VITAE



### PERSONAL INFORMATION

#### VIOLA SALVESTRINI

Address **VIA MASACCIO 52, 50018 SCANDICCI FLORENCE, ITALY**  
Phone n. **+39 3395312049**  
Fax **+39 0557947363**  
E-mail [salvestrini.viola@gmail.com](mailto:salvestrini.viola@gmail.com)  
[viola.salvestrini@unifi.it](mailto:viola.salvestrini@unifi.it)

Nationality Italian  
Date of Birth 11/02/1991

### WORK EXPERIENCE

#### **09 May 2022-**

IFCA Cyberknife center-Villa Ulivella  
Radiation Oncology department  
Radiation Oncologist

#### **28 Jan 2022- 30 April 2022**

Erasmus Medical Center, Rotterdam, Netherlands  
Radiation Oncology department  
Research fellow

### EDUCATION AND TRAINING

#### **29 Dec 2017– 29 Dec 2021**

AOU Careggi, University of Florence, Florence, Italy  
Radiation Oncology Unit,  
Resident  
Grade 70L/70

#### **26 Jun 2017– 4 Nov 2017**

Traditional medicine practitioner replacements  
Dr. Cappelli, Scandicci FI (Italy)

#### **26 Nov 2016–18 Oct 2017**

Teacher of First Aid courses  
Soluzione srl, Florence (Italy)

#### **15 Feb 2017**

Medical qualification exam  
Order of Florence medical surgeons, Florence (Italy)

#### **2 Mar 2015–19 Oct 2016**

Training as medical student  
AOU CAREGGI, Florence (Italy)

#### **1 Oct 2010–20 Oct 2016**

Medical degree  
University of Florence, Florence (Italy)  
Grade 110L/110

**11 Jul 2016–12 Jul 2016**  
Certificate in first aid (BLS/D performer)  
University of Florence, Florence (Italy)

**12 Oct 2015–16 Dec 2015**  
First Aid Course  
P.A. Humanitas, Scandicci FI (Italy)

**13 Jul 2015–7 Aug 2015**  
English language course  
Kaplan International English, New York NY (United States)

**28 Jul 2013–24 Aug 2013**  
English language course  
Kaplan International English, New York NY (United States)

**1 Sep 2005–2 Jun 2010**  
Scientific High School  
"Bertran Russell-Isaac Newton" High School, Scandicci Florence (Italy)  
Grade 100/100

## PERSONAL SKILLS

MOTHER TONGUE(S) ITALIAN

FOREIGN LANGUAGE(S)

### ENGLISH

#### UNDERSTANDING

- Reading B2
- Listening B2

#### SPEAKING

- Spoken interaction B2
- Spoken production B2

WRITING B2

COMMUNICATION SKILLS Voluntary activities with children, elderly and disabled people.  
P.A. Humanitas, Scandicci FI (Italy)

JOB-RELATED SKILLS Good team-working skills

**SCIENTIFIC  
PUBLICATIONS**

1. Meattini I, Salvestrini V, Becherini C. Radiation therapy on the axilla after neoadjuvant chemotherapy. *Curr Opin Oncol.* 2022 Jul 16. doi: 10.1097/CCO.0000000000000882. Epub ahead of print. PMID: 35838229.
2. Salvestrini V, Becherini C, Desideri I, Caprara L, Mariotti M, Banini M, Pierossi N, Scotti V, Livi L, Bonomo P. The impact of patient preference in the treatment algorithm for recurrent/metastatic head and neck squamous cell carcinoma. *Radiol Med.* 2022 Jun 25. doi: 10.1007/s11547-022-01509-1. Epub ahead of print. PMID: 35752659.
3. Francolini, G., Loi, M., Ciccone, L.P., Detti, B., Di Cataldo, V., Pinzani, P., Salvianti, F., Salvatore, G., Sottili, M., Santini, C., Frosini, G., Visani, L., Burchini, L., Mattioli, C., Allegra, A.G., Valzano, M., Cerbai, C., Aquilano, M., Salvestrini, V., Desideri, I., Mangoni, M., Meattini, I., Livi, L. Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275) (2022) 39 (8), art. no. 119,
4. Desideri, I., Lucidi, S., Francolini, G., Meattini, I., Ciccone, L.P., Salvestrini, V., Valzano, M., Morelli, I., Angelini, L., Scotti, V., Bonomo, P., Greto, D., Terziani, F., Becherini, C., Visani, L., Livi, L. Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833) (2022) 39 (8), art. no. 113, .
5. Iori, F., Bruni, A., Cozzi, S., Ciammella, P., Di Pressa, F., Boldrini, L., Greco, C., Nardone, V., Salvestrini, V., Desideri, I., De Felice, F., Iotti, C. Can Radiotherapy Empower the Host Immune System to Counterattack Neoplastic Cells? A Systematic Review on Tumor Microenvironment Radiomodulation (2022) 29 (7), pp. 4612-4624.
6. Loi, M., Salvatore, G., Sottili, M., Calosi, L., Desideri, I., Becherini, C., Salvestrini, V., Ciccone, L.P., Stocchi, G., Meattini, I., Francolini, G., Mangoni, M., Livi, L. Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer (2022) 24 (7), pp. 1395-1402.
7. Bonomo, P., Desideri, I., Mangoni, M., Saieva, C., Loi, M., Becherini, C., Cerbai, C., Ganovelli, M., Salvestrini, V., Stocchi, G., Zani, M., Palomba, A., Livi, L. Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase 1/2 trial (2022) 169, pp. 64-70.
8. Bernini, M., Meattini, I., Saieva, C., Becherini, C., Salvestrini, V., Visani, L., Stocchi, G., Bellini, C., Lorenzetti, V., Sordi, S., Nori, J., De Benedetto, D., Desideri, I., Bianchi, S., Livi, L., Orzalesi, L. Pre-pectoral breast reconstruction: early and long-term safety evaluation of 146 unselected cases of the early pre-pectoral era of a single-institution, including cases with previous breast irradiation and post-mastectomy radiation therapy (2022) 29 (2), pp. 302-313.
9. Salvestrini, V., Iorio, G.C., Borghetti, P., De Felice, F., Greco, C., Nardone, V., Fiorentino, A., Gregucci, F., Desideri, I. The impact of modern radiotherapy on long-term cardiac sequelae in breast cancer survivor: a focus on deep inspiration breath-hold (DIBH) technique (2022) 148 (2), pp. 409-417.
10. Francolini, G., Stocchi, G., Detti, B., Di Cataldo, V., Bruni, A., Triggiani, L., Guerini, A.E., Mazzola, R., Cuccia, F., Mariotti, M., Salvestrini, V., Garlatti, P., Borghesi, S., Ingrosso, G., Bellavita, R., Aristei, C., Desideri, I., Livi, L. Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting. (2022) 127 (2), pp. 206-213.
11. Desideri, I., Francolini, G., Ciccone, L.P., Stocchi, G., Salvestrini, V., Aquilano, M., Greto, D., Bonomo, P., Meattini, I., Scotti, V., Scoccianti, S., Simontacchi, G., Livi, L. Correction to: Impact of COVID-19 on patient–doctor interaction in a complex radiation therapy facility (Supportive Care in Cancer, (2021), 29, 6, (2931-2937), 10.1007/s00520-020-05793-3) (2022) 30 (2), pp. 1891-1892.
12. Francolini, G., Detti, B., Di Cataldo, V., Garlatti, P., Aquilano, M., Allegra, A., Lucidi, S., Cerbai, C., Ciccone, L.P., Salvestrini, V., Stocchi,

- G., Guerrieri, B., Visani, L., Loi, M., Desideri, I., Mangoni, M., Meattini, I., Livi, L. Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719) (2022) .
13. Salvestrini, V., Becherini, C., Desideri, I., Caprara, L., Mariotti, M., Banini, M., Pierossi, N., Scotti, V., Livi, L., Bonomo, P. The impact of patient preference in the treatment algorithm for recurrent/metastatic head and neck squamous cell carcinoma (2022) .
  14. Francolini, G., Loi, M., Di Cataldo, V., Detti, B., Stocchi, G., Masi, L., Doro, R., Scoccimarro, E., Bellini, C., Aquilano, M., Allegra, A.G., Peruzzi, A., Guerrieri, B., Morelli, I., Valzano, M., Ciccone, L.P., Salvestrini, V., Desideri, I., Livi, L. Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years (2022) 34 (1), pp. 50-56.
  15. Salvestrini, V., Greco, C., Guerini, A.E., Longo, S., Nardone, V., Boldrini, L., Desideri, I., De Felice, F. The role of feature-based radiomics for predicting response and radiation injury after stereotactic radiation therapy for brain metastases: A critical review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (yAIRO) (2022) 15 (1), art. no. 101275, .
  16. Francolini, G., Bellini, C., Di Cataldo, V., Detti, B., Bruni, A., Alicino, G., Triggiani, L., La Mattina, S., D'Angelillo, R.M., Demofonti, C., Mazzola, R., Cuccia, F., Alongi, F., Aquilano, M., Allegra, A.G., Ciccone, L.P., Burchini, L., Salvestrini, V., Morelli, I., Frosini, G., Desideri, I., Livi, L. Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis (2022) 34 (1), pp. 57-62.
  17. Greto, D., Loi, M., Stocchi, G., Salvestrini, V., Muratori, F., Scoccianti, G., Roselli, G., Palomba, A., Lorenzetti, V., Cerbai, C., Desideri, I., Francolini, G., Bonomo, P., Campanacci, D.A., Livi, L. Stereotactic Body Radiotherapy in Oligometastatic/Oligoprogressive Sarcoma: Safety and Effectiveness beyond Intrinsic Radiosensitivity (2021) 27 (6), pp. 423-427.
  18. Francolini, G., Loi, M., Salvestrini, V., Mangoni, M., Detti, B., Di Cataldo, V., Aquilano, M., Pinzani, P., Salvianti, F., Desideri, I., Mariotti, M., Garlatti, P., Stocchi, G., Ciccone, L.P., Lucidi, S., Salvatore, G., Sottili, M., Meattini, I., Livi, L. Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275) (2021) 38 (5), pp. 451-458.
  19. De Felice, F., Boldrini, L., Greco, C., Nardone, V., Salvestrini, V., Desideri, I. ESTRO vision 2030: the young Italian Association of Radiotherapy and Clinical Oncology (yAIRO) commitment statement (2021) 126 (10), pp. 1374-1376.
  20. Francolini, G., Detti, B., Becherini, C., Caini, S., Ingrosso, G., Di Cataldo, V., Stocchi, G., Salvestrini, V., Lancia, A., Scartoni, D., Giacomelli, I., Sardaro, A., Carbonara, R., Borghesi, S., Aristei, C., Livi, L. Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: A systematic review and meta-analysis of the current literature (2021) 165, art. no. 103432, .
  21. Perna, M., Scotti, V., Ciammella, P., Borghetti, P., D'angelo, E., Levra, N.G., Fozza, A., Mariotti, M., Salvestrini, V., Bertolini, F., Vagge, S., Taraborrelli, M., Falcinelli, L., Taddeo, A., Rossi, R., Costantino, G., Frassinelli, L., Filippi, A.R., Greco, C., Franceschini, D., Genovesi, D., Lohr, F., Magrini, S.M., Alongi, F., Livi, L., Bruni, A. The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC (2021) 22 (5), pp. e767-e773.
  22. Desideri, I., Francolini, G., Ciccone, L.P., Stocchi, G., Salvestrini, V., Aquilano, M., Greto, D., Bonomo, P., Meattini, I., Scotti, V., Scoccianti, S., Simontacchi, G., Livi, L.
  23. Impact of COVID-19 on patient–doctor interaction in a complex radiation therapy facility (2021) 29 (6), pp. 2931-2937. Iorio, G.C., Salvestrini, V., Borghetti, P., De Felice, F., Greco, C., Nardone, V., Fiorentino, A., Gregucci, F., Desideri, I.
  24. The impact of modern radiotherapy on radiation-induced late sequelae:

Focus on early-stage mediastinal classical Hodgkin Lymphoma. A critical review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) (2021) 161, art. no. 103326, .

25. Francolini, G., Desideri, I., Stocchi, G., Ciccone, L.P., Salvestrini, V., Garlatti, P., Aquilano, M., Greto, D., Bonomo, P., Meattini, I., Scotti, V., Scoccianti, S., Simontacchi, G., Livi, L. Impact of COVID-19 on workload burden of a complex radiotherapy facility (2021) 126 (5), pp. 717-721.
26. Bruni, A., Stefani, A., Perna, M., Borghetti, P., Levra, N.G., D'Angelo, E., D'Onofrio, A., Rubino, L., Frassinelli, L., Salvestrini, V., Mariotti, M., Alongi, F., Gonfiotti, A., Livi, L., Scotti, V.
27. Livi, L., Barletta, G., Martella, F., Saieva, C., Desideri, I., Bacci, C., Del Bene, M.R., Airoidi, M., Amoroso, D., Coltelli, L., Scotti, V., Becherini, C., Visani, L., Salvestrini, V., Mariotti, M., Pedani, F., Bernini, M., Sanchez, L., Orzalesi, L., Nori, J., Bianchi, S., Olivotto, I., Meattini, I. Cardioprotective Strategy for Patients with Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial (2021) .
28. Salvestrini, V., Mariotti, M., Banini, M., Becherini, C., Visani, L., Scotti, V., Desideri, I., Livi, L., Meattini, I. Is there a worthwhile value in personalizing radiation therapy for breast cancer patients? Time for a new paradigm in the older adult population (2021) 6 (3), pp. 157-160.
29. Bruni, A., Stefani, A., Perna, M., Borghetti, P., Levra, N.G., D'Angelo, E., D'Onofrio, A., Rubino, L., Frassinelli, L., Salvestrini, V., Mariotti, M., Alongi, F., Gonfiotti, A., Livi, L., Scotti, V. The role of postoperative radiotherapy for thymomas: A multicentric retrospective evaluation from three Italian centers and review of the literature (2020) 12 (12), pp. 7518-7530.
30. Desideri, I., Becherini, C., Visani, L., Stocchi, G., Scoccimarro, E., Mariotti, M., Salvestrini, V., Scoccianti, S., Greto, D., Bonomo, P., Pecchioli, G., Bordi, L., Della Puppa, A., Francolini, G., Meattini, I., Livi, L. Outcome and prognostic factors for older patients undergoing radiosurgery for brain metastases (2020) 11 (7), pp. 1103-1107.
31. Loi, M., Desideri, I., Dominici, L., Francolini, G., Garlatti, P., Ciccone, L.P., Stocchi, G., Salvestrini, V., Meattini, I., Livi, L. Thermal Ablation versus SBRT in liver tumours: pros and cons (2020) 37 (6), art. no. 52, .
32. Francolini, G., Desideri, I., Stocchi, G., Salvestrini, V., Ciccone, L.P., Garlatti, P., Loi, M., Livi, L. Artificial Intelligence in radiotherapy: state of the art and future directions (2020) 37 (6), art. no. 50,
33. Meattini, I., Poortmans, P., Kirova, Y., Saieva, C., Visani, L., Salvestrini, V., Kim, J., Jung, W., Olmetto, E., Mariotti, M., Desideri, I., Fourquet, A., Livi, L., Kim, K. Hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-centre comparative study. (2020) 59 (2), pp. 188-195.
34. Salvestrini, V., Desideri, I., Livi, L. Recent advances in de-intensification of radiotherapy in elderly cancer patients (2020) 9, art. no. 447, .
35. Bonomo, P., Greto, D., Desideri, I., Loi, M., Di Cataldo, V., Orlandi, E., Iacovelli, N.A., Becherini, C., Visani, L., Salvestrini, V., Mariotti, M., Livi, L. Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal? (2019) 93, pp. 1-7.
36. Livi, L., Scotti, V., Desideri, I., Saieva, C., Cecchini, S., Francolini, G., Becherini, C., Delli Paoli, C., Visani, L., Salvestrini, V., De Feo, M.L., Nori, J., Bernini, M., Sanchez, L., Orzalesi, L., Bianchi, S., Meattini, I. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial(2019) 108, pp. 100-110.

### **Abstracts**

1. P. Bonomo, I. Desideri, M. Loi, L.P. Ciccone, M. Lo Russo, C. Becherini, L. Visani, V. Salvestrini, M. Mariotti, N. Pimpinelli, L. Livi. PO-148: Management of bio-radiation dermatitis in HNSCC: emphasizing the role of calcium alginate dressings. *Radiother Oncol* (132) March: Supplement 1, Pages 78–79.

2. P. Bonomo, I. Desideri, C. Becherini, M. Loi, E. Orlandi, N.A. Iacovelli, V. Salvestrini, M. Mariotti, L. Visani, L. Livi. PO-09: Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic HNSCC. *Radiother Oncol* 2019 (132) March: Supplement 1, Pages 50–51.
3. Meattini, Y. Kirova, C. Saieva, L. Visani, E. Olmetto, V. Salvestrini, J. Kim, W. Jung, I. Desideri, A. Fourquet, P. Poortmans, L. Livi, K. Kim. PO-076: Hypofractionated whole breast irradiation safety after breast-conserving surgery for young patients. *Radiother Oncol* 2019 (133): Supplement 1, Pages S390–S391.
4. P. Bonomo, I. Desideri, C. Becherini, L. Visani, V. Salvestrini, M. Mariotti, P. Garlatti, L. Dominici, L. Livi. PO-0731: Transition from anatomical to geometric expansion modality for high-risk CTV in oropharyngeal cancer. *Radiotherapy and Oncology* 2019 (133) April: Supplement 1, Pages S375–S376
5. I Meattini, M Bernini, C Saieva, I Desideri, V Scotti, V Salvestrini, L Visani, M Mariotti, C Delli Paoli, E Olmetto, V Maragna, L Orzalesi, L Sanchez, J Nori, S Bianchi and L Livi. Abstract P3-12-07: Conservative breast reconstruction: Outcomes of 146 consecutive cases of prepectoral, subcutaneous implant-based breast reconstruction in a single-Institution series. *Cancer Research* 79 (4 Supplement): P3-12-07-P3-12-07.
6. I Meattini, V Scotti, I Desideri, C Saieva, L Visani, V Salvestrini, S Cecchini, ML De Feo, M Mariotti, E Olmetto, C Delli Paoli, G Francolini, M Bernini, L Orzalesi, L Sanchez, J Nori, S Bianchi and L Livi. Abstract P4-16-04: Oral ibandronate for osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: secondary 5-year survival outcomes analysis of the single-center phase 2 BONADIUV trial. *Cancer Research* 79 (4 Supplement): P4-16-04-P4-16-04. DOI: 10.1158/1538-7445.SABCS18-P4-16-04
7. Francolini G., Garlatti P., Detti B., Bruni A., Mantini G., Pergolizzi S., Borghetti P., D'Angelillo R.M., Alongi F., Jereczek-Fossa B.A., Franzese C., Tagliagambe A., Di Cataldo V., Aquilano M., Mariotti M., Salvestrini V., Ciccone L., Stocchi G., Livi L. P040 Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration resistant prostate cancer undergoing I line treatment with abiraterone acetate (ARTO trial-NCT03449719). *European Urology Open Science* 2020;21(Suppl 3): S150
8. PD-0411 Predictive factors of late GU toxicity after Cyberknife re-irradiation for locally recurrent PCa G. Francolini, C. Cerbai, M. Loi, V. Di Cataldo, B. Detti, G. Simontacchi, L.P. Ciccone, L. Mas, R. Doro, A. Allegra, V. Salvestrini, C. Mattioli, G. Frosini, L. Burchini, M. Aquilano, G. Stocchi, I. Desideri, L. Livi ESTRO 2022
9. OC-0605 Early outcomes of a randomized trial of SBRT and Abiraterone in mCPRC: ARTO trial NCT03449719. G. Francolini, B. Detti, V. Di Cataldo, S. Caini, A.R. Alitto, S. Parisi, C. Demofonti, A. Bruni, G. Ingrosso, G. Timon, A. Tagliagambe, M. Aquilano, L.P. Ciccone, V. Salvestrini, G. Frosini, C. Cerbai, A. Allegra, L. Burchini, I Desideri, M. Mangoni, I. Meattini, L. Livi. ESTRO 2022
10. PO-1137 Safety And Efficacy Of Silibinin In Patients With Brain Metastases after Radiosurgery: Sustain Trial I. Desideri<sup>1</sup>, L. Visani<sup>2</sup>, V. Salvestrini<sup>1</sup>, M. Mariotti<sup>1</sup>, M. Banini<sup>1</sup>, L. Angelini<sup>1</sup>, M.G. Carnevale<sup>1</sup>, I. Bonaparte<sup>1</sup>, L. Zisca<sup>1</sup>, B. Detti<sup>2</sup>, D. Greto<sup>2</sup>, I. Meattini<sup>1</sup>, L. Livi ESTRO 2022
11. PO-1299 Charlson Comorbidity Index for patients selection in definitive chemoradiation for anal carcinoma S. Lucidi<sup>1</sup>, A. Romei<sup>1</sup>, N. Bertini<sup>1</sup>, M. Loi<sup>2</sup>, P. Bonomo<sup>2</sup>, I. Desideri<sup>3</sup>, V. Di Cataldo<sup>4</sup>, B. Detti<sup>3</sup>, M. Casati<sup>5</sup>, M. Zani<sup>5</sup>, C. Arilli<sup>5</sup>, V. Salvestrini<sup>1</sup>, M. Roghi<sup>1</sup>, M. Aquilano<sup>1</sup>, M. Ganovelli<sup>1</sup>, M. Banini<sup>1</sup>, M. Valzano<sup>1</sup>, C. Bellini<sup>1</sup>, I. Meattini<sup>1</sup>, L. Livi<sup>1</sup>

## ESTRO 2022

12. PO-1363 Detection rate of 68Ga-PSMA PET/CT from a prospective study: PSICHE trial (NCT05022914) G. Francolini<sup>1</sup>, V. Di Cataldo<sup>2</sup>, B. Detti<sup>1</sup>, A. Allegra<sup>3</sup>, L. Burchini<sup>3</sup>, L.P. Ciccone<sup>3</sup>, C. Cerbai<sup>3</sup>, C. Mattioli<sup>3</sup>, G. Frosini<sup>3</sup>, B. Guerrieri<sup>3</sup>, M. Aquilano<sup>3</sup>, V. Salvestrini<sup>3</sup>, A. Chiti<sup>4</sup>, M. Sollini<sup>4</sup>, G. Simontacchi<sup>1</sup>, I. Desideri<sup>3</sup>, L. Livi<sup>5</sup> ESTRO 2022
13. P032 - P032 Radiosurgery for brain metastases from breast cancer. Poster Presenter ISRS 2022
14. P033 - P033 Single versus multiples shorts dose planning for Gamma Knife. Radiosurgery of brain metastases. Poster Presenter ISRS 2022
15. OP34 - OP34 Preoperative robotic stereotactic radiotherapy in early breast cancer: phase II ROCK trial (NCT03520894). Free Paper Speaker. ISRS 2022
16. ONCOD-14. The use of antiperspirant/deodorant during breast radiotherapy and the effect on acute radiation dermatitis: a systematic review and meta-analysis. Viola Salvestrini<sup>1</sup>, Gustavo Nader Marta<sup>2</sup>, Saverio Caini<sup>3</sup>, Mara Beveridge<sup>4</sup>, Pierluigi Bonomo<sup>5</sup>, Edward Chow<sup>6</sup>, Corina van den Hurk<sup>7</sup>, Henry Lam<sup>8</sup>, Julie Ryan Wolf<sup>9</sup>, Tara Behroozian<sup>10</sup>, On behalf of the Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group Radiation Dermatitis Guidelines Working Group. Poster Presenter at MASCC 2022 (Supp.Care in Cancer)

### **Major Invited Speeches**

1. C30 - BREAKFAST SEMINAR - Update on Emerging Body SBRT. 22 June 2022 Pre-operative SBRT for breast cancer. Invitation as Keynote Speaker ISRS 2022
2. Zoom AIRO Breast. Invitation as speaker on "Node irradiation in breast cancer". May 2022. Florence AIRO Breast group 2022.
3. Presenter "SBRT In Oligometastatic Soft Tissue Sarcoma: Long-term Survival Case", AIRO (Italian Association of Radiation Oncologist), Italy, December 2020.
2. Presenter "Treatment of recurrent-metastatic head and neck squamous cell carcinoma: new scenarios and new therapeutic opportunities", Italy, March 2021.
3. Presenter "Locally advanced pancreatic cancer, Clinical case" WRITING THE FUTURE TOGETHER, young AIOM\_AIRO\_SICO Italy, October 2021
4. Moderator of a session of young AIRO congress: "Cancer patients' quality of life and artificial intelligence" Italy, October 2021

### **DECEMBER 2020-2022**

Board member for the young group of  
AIRO (Italian Association of Radiation Oncologist)

### **OCTOBER 2019**

Attendance to EORTC Soft Tissue and Bone Sarcoma Group MEETING  
Madrid, Spain (17th-18th Oct 2019)

**COURSES  
AND  
CONGRESSES**

**APRIL 2019**

Attendance to 38thESTRO Congress  
(European Society for Radiotherapy & Oncology)  
Milan, Italy(26th –30th April 2019).

**FEBRUARY 2019**

Referent for AIRO Journal Club for Head and Neck Cancer  
(January-February 2019).

**SEPTEMBER 2018**

Attendance to EORTC BREAST CANCER GROUP MEETING –  
Warsaw, Poland (14th -15th September 2018)  
Sub-Investigator MK-3475-412 Network: KEYNOTE  
412. A Study of Pembrolizumab or placebo in  
combination with chemoradiation (CRT) in subjects  
with locally advanced HNSCC.

**RESEARCH**

Sub.investigator DUCRO-HN trial. Anti PD-L1  
Durvalumab (MEDI4736) combined with cetuximab  
and radiotherapy in locally advanced squamous cell  
carcinoma of the head and neck: a phase I/II study  
(DUCRO–HN) NCT Number: NCT03051906

Sub.investigator INTERLINK-1 (D7310C00001)  
A Phase 3 Randomized, Double-blind, Multicenter,  
Global Study of Monalizumab or Placebo in  
Combination With Cetuximab in Patients  
With Recurrent or Metastatic Squamous Cell  
Carcinoma of the Head and Neck Previously Treated  
With an Immune Checkpoint Inhibitor

Sub.investigator UPSTREAM 1559 A pilot study of  
personalized biomarker-based treatment strategy or  
immunotherapy in patients with recurrent/metastatic  
squamous cell carcinoma of the head and neck

July 27<sup>th</sup>, 2022  
Viola Salvestrini, MD

